194 related articles for article (PubMed ID: 31621581)
1. Identification of an allosteric binding site on the human glycine transporter, GlyT2, for bioactive lipid analgesics.
Mostyn SN; Wilson KA; Schumann-Gillett A; Frangos ZJ; Shimmon S; Rawling T; Ryan RM; O'Mara ML; Vandenberg RJ
Elife; 2019 Oct; 8():. PubMed ID: 31621581
[TBL] [Abstract][Full Text] [Related]
2. Membrane cholesterol regulates inhibition and substrate transport by the glycine transporter, GlyT2.
Frangos ZJ; Wilson KA; Aitken HM; Cantwell Chater R; Vandenberg RJ; O'Mara ML
Life Sci Alliance; 2023 Apr; 6(4):. PubMed ID: 36690444
[TBL] [Abstract][Full Text] [Related]
3. The allosteric inhibition of glycine transporter 2 by bioactive lipid analgesics is controlled by penetration into a deep lipid cavity.
Wilson KA; Mostyn SN; Frangos ZJ; Shimmon S; Rawling T; Vandenberg RJ; O'Mara ML
J Biol Chem; 2021; 296():100282. PubMed ID: 33450225
[TBL] [Abstract][Full Text] [Related]
4. Identification of a 3rd Na+ Binding Site of the Glycine Transporter, GlyT2.
Subramanian N; Scopelitti AJ; Carland JE; Ryan RM; O'Mara ML; Vandenberg RJ
PLoS One; 2016; 11(6):e0157583. PubMed ID: 27337045
[TBL] [Abstract][Full Text] [Related]
5. Lipid-Based Inhibitors Act Directly on GlyT2.
Schumann-Gillett A; O'Mara ML
ACS Chem Neurosci; 2019 Mar; 10(3):1668-1678. PubMed ID: 30516373
[TBL] [Abstract][Full Text] [Related]
6. Lipid inhibitors of high affinity glycine transporters: identification of a novel class of analgesics.
Carland JE; Handford CA; Ryan RM; Vandenberg RJ
Neurochem Int; 2014 Jul; 73():211-6. PubMed ID: 24036283
[TBL] [Abstract][Full Text] [Related]
7. Molecular Determinants for Substrate Interactions with the Glycine Transporter GlyT2.
Carland JE; Thomas M; Mostyn SN; Subramanian N; O'Mara ML; Ryan RM; Vandenberg RJ
ACS Chem Neurosci; 2018 Mar; 9(3):603-614. PubMed ID: 29120604
[TBL] [Abstract][Full Text] [Related]
8. Novel Phenylene Lipids That Are Positive Allosteric Modulators of Glycine Receptors and Inhibitors of Glycine Transporter 2.
Gallagher CI; Frangos ZJ; Sheipouri D; Shimmon S; Duman MN; Jayakumar S; Cioffi CL; Rawling T; Vandenberg RJ
ACS Chem Neurosci; 2023 Aug; 14(15):2634-2647. PubMed ID: 37466545
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of the analgesic GlyT2 inhibitor, ORG25543, is determined by two connected allosteric sites.
Chater RC; Quinn AS; Wilson K; Frangos ZJ; Sutton P; Jayakumar S; Cioffi CL; O'Mara ML; Vandenberg RJ
J Neurochem; 2023 Dec; ():. PubMed ID: 38131125
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the transport kinetics of glycine transporter 1 and glycine transporter 2.
Erdem FA; Ilic M; Koppensteiner P; Gołacki J; Lubec G; Freissmuth M; Sandtner W
J Gen Physiol; 2019 Aug; 151(8):1035-1050. PubMed ID: 31270129
[TBL] [Abstract][Full Text] [Related]
11. An aspartate residue in the external vestibule of GLYT2 (glycine transporter 2) controls cation access and transport coupling.
Pérez-Siles G; Núñez E; Morreale A; Jiménez E; Leo-Macías A; Pita G; Cherubino F; Sangaletti R; Bossi E; Ortíz AR; Aragón C; López-Corcuera B
Biochem J; 2012 Mar; 442(2):323-34. PubMed ID: 22132725
[TBL] [Abstract][Full Text] [Related]
12. Oleoyl-L-carnitine inhibits glycine transport by GlyT2.
Carland JE; Mansfield RE; Ryan RM; Vandenberg RJ
Br J Pharmacol; 2013 Feb; 168(4):891-902. PubMed ID: 22978602
[TBL] [Abstract][Full Text] [Related]
13. Extracellular loops 2 and 4 of GLYT2 are required for N-arachidonylglycine inhibition of glycine transport.
Edington AR; McKinzie AA; Reynolds AJ; Kassiou M; Ryan RM; Vandenberg RJ
J Biol Chem; 2009 Dec; 284(52):36424-36430. PubMed ID: 19875446
[TBL] [Abstract][Full Text] [Related]
14. MS Binding Assays for Glycine Transporter 2 (GlyT2) Employing Org25543 as Reporter Ligand.
Ackermann TM; Allmendinger L; Höfner G; Wanner KT
ChemMedChem; 2021 Jan; 16(1):199-215. PubMed ID: 32734692
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Characterization of Novel Acyl-Glycine Inhibitors of GlyT2.
Mostyn SN; Carland JE; Shimmon S; Ryan RM; Rawling T; Vandenberg RJ
ACS Chem Neurosci; 2017 Sep; 8(9):1949-1959. PubMed ID: 28574249
[TBL] [Abstract][Full Text] [Related]
16. Development of an N-Acyl Amino Acid That Selectively Inhibits the Glycine Transporter 2 To Produce Analgesia in a Rat Model of Chronic Pain.
Mostyn SN; Rawling T; Mohammadi S; Shimmon S; Frangos ZJ; Sarker S; Yousuf A; Vetter I; Ryan RM; Christie MJ; Vandenberg RJ
J Med Chem; 2019 Mar; 62(5):2466-2484. PubMed ID: 30714733
[TBL] [Abstract][Full Text] [Related]
17. Structural Determinants of the Neuronal Glycine Transporter 2 for the Selective Inhibitors ALX1393 and ORG25543.
Benito-Muñoz C; Perona A; Felipe R; Pérez-Siles G; Núñez E; Aragón C; López-Corcuera B
ACS Chem Neurosci; 2021 Jun; 12(11):1860-1872. PubMed ID: 34003005
[TBL] [Abstract][Full Text] [Related]
18. Reversible inhibition of the glycine transporter GlyT2 circumvents acute toxicity while preserving efficacy in the treatment of pain.
Mingorance-Le Meur A; Ghisdal P; Mullier B; De Ron P; Downey P; Van Der Perren C; Declercq V; Cornelis S; Famelart M; Van Asperen J; Jnoff E; Courade JP
Br J Pharmacol; 2013 Nov; 170(5):1053-63. PubMed ID: 23962079
[TBL] [Abstract][Full Text] [Related]
19. Transmembrane domains 1 and 3 of the glycine transporter GLYT1 contain structural determinants of N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)-propyl]sarcosine specificity.
Núñez E; Martínez-Maza R; Geerlings A; Aragón C; López-Corcuera B
Neuropharmacology; 2005 Nov; 49(6):922-34. PubMed ID: 16143353
[TBL] [Abstract][Full Text] [Related]
20. Molecular basis of the dominant negative effect of a glycine transporter 2 mutation associated with hyperekplexia.
Arribas-González E; de Juan-Sanz J; Aragón C; López-Corcuera B
J Biol Chem; 2015 Jan; 290(4):2150-65. PubMed ID: 25480793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
